Table 5.

Characteristics of the two protein-based vaccines targeting meningococci B

Vaccine	Bexsero®	Trumenba®
Composition	fHbp variant1 (subfamily B): 50 µg NHBA 50 µg NadA 50 µg PorA P1.4 25 µg	Lipidated proteines of:fHbp variant1 (subfamily B): 60 µg fHbp variant3 (subfamily AB): 60 µg
Licensure	Europe (EMA) (2013): ≥2 mo USA FDA (2015): ≥10 y	Europe (EMA) (20173): ≥10 y mo USA FDA (2015) ≥ 10 y
Schedule <10 y)	2 Mo-2y: 2 + 1 > 2 y-10y: 2 doses (0–2mo)	-
Schedule ≥ 10 y	> 10 y: 2 doses (0–1mo); booster unknown	2 doses (0–6mo) or 3 doses (0–1/2-6mo); booster unknown
Persistence of the immune response	Infants and toddlers 24–36 mo after booster Adolescents 4–7.5 years	4–5 y
Estimation of strain converge	78% (CI 63–90)	91% (71.5–99.3)*
Impact on acquisition of carriage	No	No
Protection against non-B isolates	Yes	Yes

*Range of coverage against reference strains.